In:
Scientific Reports, Springer Science and Business Media LLC, Vol. 11, No. 1 ( 2021-01-13)
Abstract:
The search continues for improved therapy for acute lymphoblastic leukemia ( a LL), the most common malignancy in children. Recently, d , l -methadone was put forth as sensitizer for a LL chemotherapy. However, the specific target of d , l -methadone in leukemic cells and the mechanism by which it induces leukemic cell apoptosis remain to be defined. Here, we demonstrate that d , l -methadone induces leukemic cell apoptosis through activation of the mu1 subtype of opioid receptors (OPRM1). d , l -Methadone evokes IP3R-mediated ER Ca 2+ release that is inhibited by OPRM1 loss. In addition, the rate of Ca 2+ extrusion following d , l -methadone treatment is reduced, but is accelerated by loss of OPRM1. These d , l -methadone effects cause a lethal rise in [Ca 2+ ] i that is again inhibited by OPRM1 loss, which then prevents d , l -methadone-induced apoptosis that is associated with activation of calpain-1, truncation of Bid, cytochrome C release, and proteolysis of caspase-3/12. Chelating intracellular Ca 2+ with BAPTA-AM reverses d , l -methadone-induced apoptosis, establishing a link between the rise in [Ca 2+ ] i and d , l -methadone-induced apoptosis. Altogether, our findings point to OPRM1 as a specific target of d , l -methadone in leukemic cells, and that OPRM1 activation by d , l -methadone disrupts IP3R-mediated ER Ca 2+ release and rate of Ca 2+ efflux, causing a rise in [Ca 2+ ] i that upregulates the calpain-1-Bid-cytochrome C-caspase-3/12 apoptotic pathway.
Type of Medium:
Online Resource
ISSN:
2045-2322
DOI:
10.1038/s41598-020-80520-w
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2021
detail.hit.zdb_id:
2615211-3
Permalink